JNJ vs. SKHY: Johnson & Johnson vs. SK hynix Stock Comparison

Company Profile

Johnson & Johnson (JNJ) is classified in the Health Care sector (Pharmaceuticals, Biotechnology & Life Sciences), whereas SK hynix (SKHY) belongs to Information Technology (Semiconductors & Semiconductor Equipment) — their GICS classifications point to very different parts of the market.

Johnson & Johnson (JNJ) has been public since January 2, 1962, giving it decades of market history across multiple cycles, while SK hynix (SKHY) listed only on July 10, 2026 and lacks comparable through-cycle data.

Johnson & Johnson (JNJ) trades as ordinary local shares, while SK hynix (SKHY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

SK hynix (SKHY) has a highly aggressive beta of 5.36, indicating much higher sensitivity to broad-market moves, while Johnson & Johnson (JNJ) is defensive at 0.21 and tends to be less market-sensitive — a wide gap in beta profiles.

Risk-Adjusted Performance

Risk-Return Positioning

Both JNJ and SKHY need 1-year volatility and 1-year return to plot risk-return positioning.

Risk-Adjusted Metrics

Profitability

Both companies show strong equity returns, but SK hynix (SKHY) at 92.54% is the standout with ROE above its industry range; Johnson & Johnson (JNJ) at 20.02% also sits in the top quartile.

SK hynix (SKHY) at 70.27% keeps the most of each sales dollar — above its industry’s net margin range — and Johnson & Johnson (JNJ) at 16.20% also retains a top-quartile share.

SK hynix (SKHY) at 79.66% shows unusually strong operating efficiency — above its industry’s operating margin range — and Johnson & Johnson (JNJ) at 25.74% also operates in the top quartile.

Profitability Metrics

Growth

SK hynix (SKHY) at 46.76% sits in the top revenue growth quartile, while Johnson & Johnson (JNJ) at 6.05% is closer to the peer norm — faster top-line expansion for SKHY.

Both Johnson & Johnson (JNJ) at 90.50% and SK hynix (SKHY) at 112.46% sit in the top peer quartile for EPS growth, so each is compounding per-share earnings faster than typical industry peers.

Growth Metrics

Financial Strength

SK hynix (SKHY) at 26.88 carries current ratio above its industry’s typical mid-range, while Johnson & Johnson (JNJ) at 1.02 runs in the tighter-liquidity quartile — different working-capital profiles, both worth examining.

Both Johnson & Johnson (JNJ) at 0.55 and SK hynix (SKHY) at 0.05 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Both Johnson & Johnson (JNJ) at 1.94% and SK hynix (SKHY) at 2,118.64% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

SK hynix (SKHY) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Johnson & Johnson (JNJ) reports a payout of 80.12%, ranking against industry peers normally.

Dividend Metrics

Valuation

SK hynix (SKHY) at 8.12 sits in the cheaper P/E ratio quartile, while Johnson & Johnson (JNJ) at 41.92 is closer to its industry’s usual earnings multiple — a discount for SKHY, though growth and earnings durability still matter.

SK hynix (SKHY) at 0.00 sits in the cheaper P/S ratio quartile while Johnson & Johnson (JNJ) at 6.69 prices around its industry’s middle — SKHY costs less per dollar of sales, though read it alongside growth and margins.

SK hynix (SKHY) at 3.95 is valued about in line with its industry on P/B ratio, while Johnson & Johnson (JNJ) at 8.16 carries an above-peer premium to book — JNJ is pricier on assets.

Valuation Metrics